VI-0521 oral capsule for pediatric obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Apr 2019: Trial registered, NCT03922945
  2. 2 May 2019: Trial started, NCT03922945

The trials

NCT03922945: A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity

State
Completed
Phase
Phase 4
People
223 taking part
Started
2 May 2019
Primary completion
16 Apr 2021
Arms
VI-0521 Mid Dose (Phentermine 7.5 mg +Topiramate 46 mg), VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg)
Results
Posted on the registry
  1. 22 Apr 2019: Trial registered
  2. 2 May 2019: Trial started
  3. 16 Apr 2021: Trial completed
  4. 10 Sep 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.